Owonikoko, T., Papadopoulos, K., Johnson, M. and al., et 2019. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data. SKIN The Journal of Cutaneous Medicine. 3, 2 (Mar. 2019), 169. DOI:https://doi.org/10.25251/skin.3.2.9.